Nasdaq

Nurix Therapeutics Showcases Promising Preclinical Data for BTK, BRAF, and Aurora A Kinase Degraders at AACR 2025 Annual Meeting

Nurix Therapeutics, Inc. presented promising preclinical data at the AACR 2025 Annual Meeting, showcasing their innovative targeted protein degradation medicines aimed at addressing various cancers, ...
ascopubs.org

Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations

Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen ...
Seeking Alpha

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value ...

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BRAF degrader demonstrates broad activity ...

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...
Pharm Exec

FDA Grants Full Approval to Braftovi Combination for First-Line BRAF V600E–Mutant Metastatic Colorectal Cancer

Full approval was driven by BREAKWATER Phase III outcomes, including PFS HR 0.53 and OS HR 0.49 versus fluoropyrimidine/oxaliplatin-based chemotherapy options ± ...